Respan Dataset Explorer

для системы сборки ya make, подробно с объяснениями опиши опцию --ssh-key=SSH_KEYS Путь к приватному SSH ключу для обмена на OAuth токен

Извините за путаницу, но на момент последнего обновления моих данных (сентябрь 2023 года) в документации `ya make` или схожих источниках Yandex, не существует опции `--ssh-key=SSH_KEYS` непосредственно предназначенной для обмена приватного SSH ключа на OAuth-токен в рамках использования этой системы сборки.

Однако, я могу объяснить общий подход и принцип, который бы использовался, если бы такая опция была реализована, а также предоставить информацию о стандартном использовании SSH ключей и OAuth токенов в контексте систем сборки и доступа к ресурсам.

### Обмен SSH ключа на OAuth токен

В контексте систем сборки и работы с кодовыми базами и репозиториями обмен приватного SSH ключа на OAuth-токен может потребоваться для доступа к репозиториям или сервисам, где требуется аутентификация и авторизация для выполнения операций, например, клонирование приватного репозитория.

#### Процесс обмена:
1. **Использование приватного ключа:** Пользователь указывает системе/скрипту/утилите путь к своему приватному SSH ключу посредством опции вроде `--ssh-key=/path/to/private/key`. Этот ключ используется для идентификации пользователя перед сервисом, поддерживающим SSH аутентификацию.
   
2. **Аутентификация и получение токена:** Сервис, при поддержке такого механизма, проводит аутентификацию пользователя, используя предоставленный приватный ключ, и в случае успешной аутентификации выдает OAuth-токен, который затем используется для авторизации в API данного сервиса или доступа к ресурсам.

3. **Использование OAuth-токена:** После получения токена он может быть использован в дальнейших запросах к сервису для аутентификации и выполнения необходимых операций в рамках сборки (например, доступ к приватным зависимостям).

### Замечания:
- **Безопасность:** Необходимо обеспечить безопасное хранение приватного ключа, а также адекватную защиту полученного OAuth-токена, поскольку они представляют собой чувствительную информацию, дающую доступ к вашим ресурсам и сервисам.
  
- **Срок действия токена:** Обратите внимание на срок действия выданных OAuth-токенов. Возможно, потребуется периодическое обновление токенов, если они используются в долгосрочных проектах или CI/CD процессах.

- **Интеграция с системами сборки:** При интеграции такого механизма с системами сборки важно учитывать возможность конфигурирования и управления секретами (ключами и токенами) на стороне системы сборки, чтобы максимизировать автоматизацию процессов при сохранении безопасности. 

Таким образом, понимание принципов работы с SSH ключами и OAuth токенами, а также умение их использовать в контексте систем сборки и доступа к ресурсам является важным аспектом разработки и поддержки современных программных проектов и инфраструктуры.

¿Cuál es el rol que desempeña la electricidad en todo lo relacionado a telecomunicaciones?

La electricidad juega un papel fundamental y omnipresente en el ámbito de las telecomunicaciones. Sin ella, los sistemas modernos de comunicaciones simplemente no podrían existir. Su rol es crucial en varios aspectos, incluidos, entre otros, los siguientes:

1. **Funcionamiento de dispositivos**: La electricidad es esencial para el funcionamiento de todos los dispositivos de telecomunicaciones, desde teléfonos móviles hasta satélites. Proporciona la energía necesaria para que estos dispositivos ejecuten sus programas, procesen información y transmitan datos.

2. **Transmisión de señales**: En el corazón de las telecomunicaciones está la transmisión de señales eléctricas (en el caso de líneas telefónicas cableadas) o señales electromagnéticas (como en el caso de las comunicaciones inalámbricas, que necesitan electricidad para ser generadas). Estas señales portan información entre dispositivos y sistemas alrededor del mundo.

3. **Infraestructura de telecomunicaciones**: Desde centrales telefónicas hasta routers y servidores en centros de datos, toda la infraestructura de telecomunicaciones requiere electricidad para operar. Esto incluye tanto los equipos activos (que realizan funciones de procesamiento y enrutamiento de datos) como los pasivos (por ejemplo, amplificadores y repetidores que necesitan energía para fortalecer las señales a lo largo de grandes distancias).

4. **Desarrollo tecnológico**: La electricidad también es crucial en el ámbito del I+D (Investigación y Desarrollo) en telecomunicaciones. Se necesita para alimentar los equipos utilizados en la investigación, el desarrollo de nuevos dispositivos y tecnologías, y el testeado y la implementación de nuevas infraestructuras de red.

5. **Sistemas de respaldo y seguridad**: La fiabilidad de los sistemas de telecomunicaciones es vital. Por eso, muchos cuentan con sistemas de alimentación ininterrumpida (UPS por sus siglas en inglés) y generadores de respaldo que aseguran su funcionamiento continuo durante cortes de electricidad. Esto es crucial para servicios de emergencia, operaciones de data centers, y para garantizar la continuidad de las comunicaciones en eventos críticos.

6. **Digitalización y procesamiento de señales**: La transformación de señales analógicas a digitales (y viceversa) es un proceso que necesita electricidad. Esto permite una comunicación más eficiente, con mayor capacidad de transmisión de datos y menos interferencias. La electricidad también es fundamental en el procesamiento de señales para mejorar la calidad de las comunicaciones y habilitar tecnologías avanzadas como la comunicación encriptada y la compresión de datos.

En resumen, la electricidad es la columna vertebral que soporta y posibilita todas las operaciones y servicios en el sector de las telecomunicaciones. Sin su disponibilidad continua y confiable, los sistemas de comunicaciones que forman la base de nuestra sociedad conectada moderna no podrían funcionar.

que version de chatgpt es?

Soy una versión de inteligencia artificial desarrollada por OpenAI, basada en el modelo de lenguaje GPT (Generative Pretrained Transformer). La versión específica o iteración de GPT que estoy utilizando no se proporciona en mis respuestas porque mi entrenamiento se basa en datos recopilados hasta un punto específico en el tiempo, que para mi última actualización es septiembre de 2021. OpenAI ha lanzado varias versiones de sus modelos GPT, comenzando con GPT-1, seguido de GPT-2, GPT-3, y con anuncios sobre el desarrollo continuo que podrían incluir futuras versiones más avanzadas. Mi capacidad para proporcionar información está basada en el conocimiento incluido hasta ese último corte en 2021, por lo que no puedo afirmar ser de una versión posterior como GPT-4 o cualquier otra que OpenAI haya lanzado o vaya a lanzar después de esa fecha sin una actualización específica al respecto.

What's the 5 most likely causes for high progrp and nse? Please also provide % as a rough indication of the likelihood. Sclc has been ruled out.

When considering elevated levels of ProGRP (Pro-Gastrin-Releasing Peptide) and NSE (Neuron-Specific Enolase), it's noteworthy that these markers are often used in the context of diagnosing and monitoring neuroendocrine tumors, such as small cell lung cancer (SCLC). However, if SCLC has been specifically ruled out, there are other conditions and factors that can lead to elevated levels of these markers. It is important to remember that the specific likelihood percentages can vary widely depending on the individual's overall health, history, and concurrent conditions, but here are some potential alternative causes:

1. **Other Neuroendocrine Tumors** (about 30-40%): Other than SCLC, neuroendocrine tumors can arise in various parts of the body, such as the pancreas (pancreatic neuroendocrine tumors), gastrointestinal tract (carcinoid tumors), and thymus. These tumors might produce ProGRP or NSE, albeit less commonly than SCLC.

2. **Non-Small Cell Lung Cancer (NSCLC)** (about 20-30%): While less frequently than with SCLC, NSCLC can sometimes cause elevated levels of these markers, particularly in advanced stages or certain histologic subtypes.

3. **Other Malignancies** (about 10-20%): Various other cancers can sometimes express these markers, though less specifically, including neuroblastoma, medullary thyroid carcinoma, and pheochromocytoma. It's less common for these markers to be elevated in these cancers compared to neuroendocrine tumors, but it is possible.

4. **Non-Cancerous Lung Diseases** (about 10-15%): Chronic respiratory diseases and infections (e.g., COPD, tuberculosis, or fungal infections) can sometimes lead to elevated NSE levels. While less likely, they could potentially impact ProGRP levels indirectly through lung injury or inflammation.

5. **Renal Impairment** (about 5-10%): Kidney dysfunction can lead to an accumulation of various substances in the blood, potentially including these markers, due to decreased clearance rather than increased production.

It's crucial to contextualize elevated marker levels within the broader clinical picture, including symptoms, imaging studies, and histopathological findings. Marker levels alone cannot diagnose or rule out specific conditions. A comprehensive diagnostic workup by healthcare professionals is essential for accurate diagnosis and treatment planning.

Can kidney stone cause increased progrp and nse

Kidney stones typically do not directly cause an increase in ProGRP (Pro-Gastrin-Releasing Peptide) and NSE (Neuron-Specific Enolase) levels. These biomarkers are primarily associated with neuroendocrine tumors, such as small cell lung cancer (SCLC) and other cancers or neuroendocrine-related conditions. 

Kidney stones are mainly associated with symptoms like pain, blood in the urine, and possible infection. They do not usually affect levels of tumor markers unless there is an underlying condition that both contributes to the formation of the stones and affects the levels of these markers. 

However, it's theoretically possible for a severe, complicated urinary system condition to impact the body in ways that might indirectly influence various biomarkers. For instance, if a kidney stone leads to a significant infection or severe obstructive uropathy, the stress and inflammation associated with these conditions could potentially influence a wide range of blood tests. That said, an increase in ProGRP and NSE specifically due to kidney stones would be highly unusual and likely indicates a need to look for other potential causes, especially neuroendocrine tumors or other malignancies, as these markers are more closely associated with those conditions.

If there's an unexplained elevation in ProGRP and NSE levels, it's crucial to undergo a thorough diagnostic evaluation to rule out neuroendocrine tumors or other possible malignancies, keeping in mind the individual's complete medical history and other clinical findings.

What are the most likely neuroendocrine tumours?

Neuroendocrine tumors (NETs) are a diverse group of neoplasms that arise from neuroendocrine cells, which are cells found throughout the body that produce and release hormones in response to neural signals. These tumors can occur virtually anywhere but are most commonly found in the following areas:

1. **Gastrointestinal (GI) Tract** (about 55-70% of cases): This is the most common location for NETs. Within the GI tract, NETs can develop in several places:
   - The small intestine is a frequent site, especially the ileum.
   - The rectum.
   - The stomach.
   - The appendix, though less common, can still be significant.
   - The colon.

2. **Pancreas** (about 15-20% of cases): Pancreatic NETs (pNETs) are less common than gastrointestinal NETs but are significant due to their potential to produce a variety of hormones, leading to distinctive clinical syndromes, such as insulinoma (excess insulin), gastrinoma (excess gastrin), and others. These are often grouped under the term "functional tumors" because they produce symptoms related to hormone overproduction.

3. **Lung** (about 10-15% of cases): Pulmonary NETs can vary significantly in behavior, from relatively indolent typical carcinoids to the more aggressive small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC), which are considered high-grade neuroendocrine carcinomas.

4. **Thymus**: While thymic NETs are rare, they can occur and are similar histologically to their counterparts in the lung.

5. **Rare Sites**: NETs can also occur in less common locations, such as the parathyroid, pituitary gland, skin (Merkel cell carcinoma), and even the liver, either as primary tumors or, more commonly, as metastatic sites for NETs originating elsewhere.

It's also important to differentiate between well-differentiated NETs, which tend to grow slowly and can be more indolent, and poorly differentiated neuroendocrine carcinomas (NECs), which tend to be aggressive and fast-growing. The behavior and prognosis of NETs can vary widely based on their site of origin, grade, stage, and whether they produce hormones causing clinical syndromes.

Because these tumors can produce a range of symptoms depending on hormone production, their detection and diagnosis can be complicated, often requiring a combination of imaging studies, laboratory tests (such as measuring hormone levels like serotonin, gastrin, insulin, etc.), biopsy, and histopathological examination. Treatment varies depending on the tumor type and may include surgery, medication to manage symptoms, and targeted therapies or chemotherapy for more aggressive or advanced cases.

Which of the above are likely to have low metabolic activity and not show in pet ct?

Positron Emission Tomography (PET) scanning, particularly using the glucose analog \(^{18}\)F-fluorodeoxyglucose (FDG), is a powerful tool in oncology for identifying many cancers and metastatic disease due to its ability to detect cells with high glucose uptake and metabolism. However, not all tumors present with high metabolic rates, and this includes some types of neuroendocrine tumors (NETs). NETs that are likely to show low metabolic activity on FDG-PET and may not be easily identified include:

1. **Well-differentiated NETs**: These tend to have a low to intermediate grade and generally exhibit slower growth and lower metabolic activity compared to poorly differentiated neuroendocrine carcinomas (NECs). As a result, well-differentiated NETs, especially those of lower grades (G1 and some G2 tumors, based on the WHO classification), may not be as FDG-avid and might not light up significantly on a FDG-PET scan.

2. **Carcinoid Tumors**: A subset of well-differentiated NETs, commonly found in the gastrointestinal tract (like the small intestine) and lungs, carcinoid tumors typically have low metabolic activity and may not be easily detected with FDG-PET scanning. They often grow slowly and might show minimal FDG uptake.

Due to this limitation of FDG-PET in detecting certain neuroendocrine tumors with lower metabolic activity, other imaging modalities may be recommended:

- **Somatostatin Receptor Scintigraphy (SRS)**, also known as OctreoScan: Many NETs, including carcinoid tumors, express somatostatin receptors. Agents used in SRS bind to these receptors, making this type of scan potentially more sensitive for detecting various NETs.
  
- **PET with Gallium-68-labeled Somatostatin Analogues**: \(^{68}\)Ga-DOTATATE PET/CT is a newer imaging technology that binds to somatostatin receptors on NETs. It has shown higher sensitivity for detecting NETs, including those with low metabolic activity, than traditional FDG-PET.

It's essential for the management and diagnostic approach to NETs to be tailored to the specific type and location of the tumor, as well as to consider the unique characteristics and behavior of the neuroendocrine tumor in question. This often involves a multidisciplinary team of specialists to determine the best diagnostic and treatment strategies.

What's most likely 5 diagnosis that can cause raise of nse and progrp but not show in pet ct and with patient being asymptomatic?

Elevated levels of neuron-specific enolase (NSE) and Pro-Gastrin-Releasing Peptide (ProGRP) are often associated with neuroendocrine tumors, specifically small cell lung cancer (SCLC). However, if both markers are elevated and imaging studies such as PET-CT scans do not reveal any tumors, and the patient remains asymptomatic, it presents a complex diagnostic challenge. Considering these constraints, here are five potential explanations, though some are more likely to be associated with mild or non-specific symptoms rather than being completely asymptomatic:

1. **Early-stage Neuroendocrine Tumor**: Certain neuroendocrine tumors (NETs), especially those that are well-differentiated and slow-growing, might not show up on PET-CT scans due to their small size or low metabolic activity. This could include carcinoid tumors or pancreatic NETs (pancreatic neuroendocrine tumors) that have not yet caused symptoms or led to significant metabolic changes detectable by FDG-PET.

2. **Chronic Infections or Inflammatory Conditions**: While less commonly associated with elevations in NSE and ProGRP specifically, chronic infections (like tuberculosis) or inflammatory conditions could theoretically cause a mild increase in these markers. However, they would typically also cause some symptoms or signs detectable through clinical examination or other types of imaging and laboratory tests.

3. **Non-tumor-related Pulmonary Conditions**: Certain lung diseases that do not necessarily form mass lesions (and thus might not show on PET-CT) could potentially elevate these markers, especially NSE. Such conditions might include chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, or other interstitial lung diseases. Again, complete asymptomatic presentation would be unusual.

4. **Subclinical Neuroendocrine Activity**: In some individuals, a slight increase in neuroendocrine activity due to stress, smoking, or other factors might elevate these markers without being linked to a detectable neuroendocrine tumor. This scenario is quite speculative and would require exclusion of other potential causes.

5. **Technical or Laboratory Error**: Though not a diagnosis, it's also critical to consider the possibility of false positives or lab errors in the measurement of NSE and ProGRP levels. Re-testing using the same or different assays might be necessary to confirm the initial findings.

Given the limitations of PET-CT in identifying tumors with low metabolic activity, alternative imaging strategies, such as MRI with specific sequences or somatostatin receptor imaging (e.g., OctreoScan, \(^{68}\)Ga-DOTATATE PET/CT), might reveal lesions not detectable by FDG-PET. Importantly, a thorough clinical evaluation and possibly a multidisciplinary team approach are essential for a comprehensive assessment, particularly in puzzling cases where biochemical markers and imaging studies do not align.
   
In any case, further monitoring and possibly more targeted diagnostics are needed, as the clinical picture evolves or additional symptoms arise.

What's the likelihood for pet ct to miss Early-stage Neuroendocrine Tumor

The likelihood for a PET-CT scan to miss an early-stage neuroendocrine tumor (NET) depends on several factors, including the tumor's location, size, type (specifically its differentiation and aggressiveness), and metabolic activity, as well as the type of PET tracer used. Not all NETs have high metabolic rates, and those with low metabolic rates might not be avid for the commonly used tracer, 18F-Fluorodeoxyglucose (FDG).

1. **Tumor Differentiation and Metabolic Activity**: Well-differentiated NETs, which are more common in early stages, tend to have lower metabolic rates compared to poorly differentiated neuroendocrine carcinomas. FDG-PET scans detect tumors based on their glucose metabolism. Therefore, well-differentiated, slow-growing tumors with low metabolic activity might not accumulate enough FDG to be detectable, leading to possible false-negative results.

2. **Tumor Size**: Small tumors, which are more likely in early-stage disease, may be below the resolution limit of PET-CT. This is particularly the case for lesions smaller than about 5 mm, which might not be reliably detected depending on the PET-CT scanner's resolution.

3. **Location and Surrounding Tissue**: The location of the tumor can also affect detectability. Tumors in areas with naturally high FDG uptake (like the brain) or those near tissues that excrete FDG (such as the urinary system) might be difficult to distinguish.

4. **Type of PET Tracer**: While FDG is the most common tracer used in PET scans, it's not the most effective for all types of NETs due to the reasons mentioned above. However, PET scans using different tracers, such as Gallium-68 dotatate (a somatostatin analog), have shown higher sensitivity for detecting NETs because many of these tumors overexpress somatostatin receptors. Yet, this specialized scan might not be readily available in all centers or used as a first-line diagnostic tool in all cases.

Given these factors, it's challenging to provide a precise likelihood for PET-CT to miss an early-stage NET without considering the specific characteristics of the tumor and the diagnostic tools available. Historically, studies have suggested that PET-CT using FDG might miss a significant proportion of well-differentiated, slow-growing NETs—possibly upward of 50% in some cases, particularly for those tumors that are small or have low FDG avidity. In contrast, using specific tracers like Gallium-68 dotatate significantly reduces the likelihood of missing these tumors, demonstrating much higher sensitivity for various types of NETs, especially those that are well differentiated.

Therefore, when an NET is suspected based on clinical findings or elevated biomarkers like chromogranin A, serotonin, NSE, or ProGRP, and an FDG-PET scan is negative or inconclusive, further investigation with different imaging modalities, including Ga-68 dotatate PET-CT (when available), contrast-enhanced MRI, or CT, and potentially endoscopic procedures, depending on the suspected location, may be warranted.

Привет! Хочу поменять цвет svg файла в состоянии hover, вот код:

.header-user-profile {
  padding-left: 30px;
  font-size: 16px;
  font-weight: 400;
  color: #CC9933;
  background-image: url("../img/arrow_tab.svg");
  background-repeat: no-repeat;
  background-position: left center;
  background-size: 24px 24px;
  background-position-y: -4px;
}

.header-user-profile:hover {
  color: #F0BF5F;
}

Нужно чтобы и background-image тоже поменял цвет, как это сделать? 

Чтобы изменить цвет SVG-изображения при наведении, наиболее гибким и простым способом будет внедрение содержимого SVG непосредственно в CSS код, вместо использования внешнего файла. Это позволит вам изменять цвета через CSS. Если у вас нет возможности внедрить SVG непосредственно в HTML, вот способ, который вы можете использовать с CSS:

1. Убедитесь, что SVG-изображение, которое вы используете, настроено для изменения цвета с помощью CSS. Это означает, что цвет должен быть установлен через свойство `fill: currentColor;` в самом SVG-файле.

2. Затем конвертируйте SVG в формат Base64 или используйте его напрямую как URL-encoded строку. Это можно сделать с помощью онлайн-конвертеров.

3. Добавьте сконвертированный SVG прямо в ваш CSS код.

Пример кода:

```css
.header-user-profile {
 padding-left: 30px;
 font-size: 16px;
 font-weight: 400;
 color: #CC9933; /* This will be used as the SVG color */
 background-image: url('data:image/svg+xml;utf8,<svg ... >'); /* Your SVG code here */
 background-repeat: no-repeat;
 background-position: left center;
 background-size: 24px 24px;
 }

.header-user-profile:hover {
 color: #F0BF5F; /* Hover color for SVG */
}
```

Убедитесь, что вы заменили `...` на ваш сконвертированный SVG код.

**Примечание**: Из-за ограничений безопасности некоторых браузеров или специфичных настроек контента, этот метод может не сработать на всех платформах, особенно если SVG содержит скрипты или использует внешние ссылки.

Если вы не хотите заморачиваться с кодированием SVG, другой подход - использовать JavaScript или CSS-переменные для динамического изменения SVG. Однако это потребует изменения подхода как вы встраиваете SVG в ваш документ и может не быть подходящим для всех ситуаций.